Mistral Pharma Announces Positive Results From a POpening volume higher than usual, could be a sign that new players are watching this stock....
IFC
MONTREAL, QUEBEC, Dec 03, 2007 (MARKET WIRE via COMTEX News Network) --
Mistral Pharma Inc. (TSX VENTURE: MIP) ("Mistral") today announced positive results from a first pilot pharmacokinetic (PK) study on a new controlled-release product, MIST-B04. The results of this pilot study clearly show that MIST-B04 presents a pharmacokinetic profile leading to a once daily dosing schedule compared to the three times daily immediate-release formulation presently on the market. MIST-B04 is formulated using a new drug delivery platform named TRIZERO(TM), which was developed internally by Mistral's scientists and for which a patent application was filed in June 2007.
"We are very excited by these positive results on MIST-B04" commented Bertrand Bolduc. "They show that our brand new TRIZERO(TM) platform is performing very well in vivo and this opens up many other opportunities for line-extension products for MIST-B04" he added.
Mistral's MIST-B04 is a controlled-delivery branded product in the rheumatology / inflammation field. According to Drug Topics, sales for the branded product targeted by MIST-B04 were more than US$ 200 M in the US in 2006.
About Mistral Pharma Inc.
Mistral Pharma Inc. is an innovative pharmaceutical company that is active in the reformulation and the commercialization of already-marketed drugs. Its branded drug delivery products, MIST-B01, MIST-B02, MIST-B03 & MIST-B04, showed positive results at their respective first pilot clinical trials. Mistral also markets INSTILLAGEL(R) in Canada, a local anesthetic and antiseptic combination product used for urology procedures. Mistral has also in-licensed TAMALIS(TM) (Rupatadine) a new antihistamine and INSTILLAQUILL(R), a single use extension tube used in gynecology. They should both be filed with Health Canada in 2008. Mistral positions itself as a development and marketing partner for pharmaceutical companies. More information is available on Mistral's website at www.mistralpharma.com.